Drugs / MK0533
last change Aug 2007 re-read 2 minutes ago

MK0533

Small molecule targets PPARG

Developed for
type 2 diabetes mellitus
Investigated by
Merck Sharp & Dohme LLC

Trials 1 · a red edge is where a trial was stopped

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00543959 Jun 2006 → Aug 2007 type 2 diabetes mellitus Merck Sharp & Dohme LLC Terminated No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as MK0533 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00543959
Modality Small molecule CHEMBL490029
Target PPARG “Peroxisome proliferator-activated receptor gamma modulator” CHEMBL490029